公开(公告)号：US20230067476A1

公开(公告)日：2023-03-02

申请号：US17520857

申请日：2021-11-08

Applicant: Novartis AG

Inventor： Claire ADCOCK ,  Simone BONAZZI ,  Artiom CERNIJENKO ,  Philip LAM ,  Kathryn Taylor LINKENS ,  Hasnain Ahmed MALIK ,  Noel Marie-France THOMSEN ,  Michael Scott VISSER

IPC: C07D401/04 ,  C07D407/14

Abstract: The present disclosure provides a compound of Formula (I′): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein Rx, X1, X2, and R1 are as defined herein, and methods of making and using same.

公开(公告)号：US20220306617A1

公开(公告)日：2022-09-29

申请号：US17638106

申请日：2020-08-24

Applicant: NOVARTIS AG

Inventor： Claire ADCOCK ,  Jake AXFORD ,  Ying HOU ,  Hyungchul KIM ,  Yiping SHEN ,  Nichola SMITH ,  Catherine Fooks SOLOVAY ,  Moo Je SUNG ,  Megan LIGHTFOOT ,  Alessandro MAZZACANI ,  Emily STANLEY ,  Lewis WHITEHEAD

IPC: C07D413/10 ,  A61K31/422 ,  A61K45/06 ,  C07D413/14 ,  A61K31/454 ,  A61K31/5377 ,  A61K31/675 ,  C07F9/6558 ,  A61P11/00

Abstract: The invention relates to heterocyclic compounds of the formula (I) in which all of the variables are as defined in the specification; capable of modulating the ctivity of TMEM16a. The invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including COPD, bronchiectasis, asthma, cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, cystic fibrosis, primary ciliary dyskinesia, respiratory tract infections (acute and chronic; viral and bacterial), lung carcinoma.

公开(公告)号：US20200017461A1

公开(公告)日：2020-01-16

申请号：US16504375

申请日：2019-07-08

Applicant: Novartis AG

Inventor： Claire ADCOCK ,  Simone BONAZZI ,  Artiom CERNIJENKO ,  Philip LAM ,  Kathryn Taylor LINKENS ,  Hasnain Ahmed MALIK ,  Noel Marie-France THOMSEN ,  Michael Scott VISSER

IPC: C07D401/04 ,  C07D407/14

Abstract: The present disclosure provides a compound of Formula (I′): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein Rx, X1, X2, and R1 are as defined herein, and methods of making and using same.